|
USA-AL-BRENT Azienda Directories
|
Azienda News:
- Serious AEFI - World Health Organization (WHO)
For infants with a delayed second or third dose of vaccine, the risk of serious AEFI was estimated for the period to the following dose, or at 24 weeks of age, or death, whichever occurred first Infants were enrolled at the time of their first dose of pentavalent and OPV vaccines and followed weekly until 4 weeks after their third dose of pentavalent vaccine
- AEFI - World Health Organization (WHO)
GACVS also emphasized the need for strengthening AEFI surveillance systems at country and regional levels to improve the current reporting of safety signals following immunization The development of regional networks could be the next step towards improving the reporting of AEFI and vaccine safety signals at the global level
- AEFI - World Health Organization (WHO)
Adverse Events Following Immunization (AEFI) Immunization stress-related responses (ISRS)
- AEFI - World Health Organization (WHO)
GACVS also emphasized that AEFI surveillance systems must be strengthened at country level and regional level to improve the reporting of safety signals following immunization Full report of GACVS meeting of 15-16 June 2011, published in the WHO Weekly Epidemiological Record on 22 July 2011
- Reporting form for AEFI - World Health Organization (WHO)
Effective spontaneous reporting of adverse events following immunization (AEFI) is the first step to making sure that vaccine products are safe and are being safely administered
- Causality assessment of an adverse event following immunization (AEFI . . .
Since the 2013 publication of the “Causality assessment of an adverse event following immunization (AEFI), user manual for the revised WHO classification”, there has been extensive global interest in adopting the new revised causality assessment methodology for vaccine pharmacovigilance systems WHO provided technical support and helped build capacity in countries of all WHO Regions who
- Innovative approaches - World Health Organization (WHO)
Members were shown how data are now being collected and used to understand the strength and capacity of AEFI reporting systems Specifically, the WHO Regional Office for Europe (EURO) presented 2022 data and showed that 45 out of the 53 Member States (85%) reported any AEFI(s) and serious AEFIs were reported by 41 Member States (81%)
- SURVEILLANCE MANUAL IMMUNIZATION (AEFIS) - World Health Organization (WHO)
AEFI investigation dossier, with all the necessary information including a ‘valid diagnosis’, details of the vaccine administered, information about medication being taken at the time of vaccination or prior to the occurrence of the AEFI and an independent AEFI causality assessment committee
- Global manual on surveillance of adverse events following immunization
This new manual provides guidance on setting-up AEFI surveillance systems with standardized methodologies and tools It addresses the investigation of AEFI, how to analyze surveillance data, causality assessment and how to respond to serious AEFI, including communication
- Vaccine safety indicator - World Health Organization (WHO)
This indicator has been the mainstay of AEFI reporting globally as part of the Global Vaccine Action Plan 7 monitoring and evaluation framework and has been used as a benchmark to evaluate the progress of vaccine safety performance at national, regional and global levels
|
|